Work

1094P Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2228

Authors: E. Burton, D. Milton, L. Simpson, M. Tetzlaff, I.C. Glitza, M.I. Ross, J.E. Gershenwald, J. Mcquade, M. Wong, S. Patel, A. Diab, M. Postow, C.E. Ariyan, J. Lee, S. Fisher, V. Prieto, M. Davies, H.A. Tawbi, J. Wargo, R. Amaria

Institutions: The University of Texas MD Anderson Cancer Center, University of California, San Francisco, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387811045

FWCI: 0.209

Cites: 1

Cited by: 2

Related to: 10